|
1
|
Ng SC, Shi HY, Hamidi N, Underwood FE,
Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JC, Chan FK, et al:
Worldwide incidence and prevalence of inflammatory bowel disease in
the 21st century: A systematic review of population-based studies.
Lancet. 390:2769–2778. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fumery M, Singh S, Dulai PS,
Gower-Rousseau C, Peyrin-Biroulet L and Sandborn WJ: Natural
history of adult ulcerative colitis in population-based cohorts: A
systematic review. Clin Gastroenterol Hepatol. 16:343–356.e3.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Harbord M, Eliakim R, Bettenworth D,
Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T,
Sebastian S, et al: Third European evidence-based consensus on
diagnosis and management of ulcerative colitis. Part 2: Current
management. J Crohns Colitis. 11:769–784. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ko CW, Singh S, Feuerstein JD, Falck-Ytter
C, Falck-Ytter Y and Cross RK: American Gastroenterological
Association Institute Clinical Guidelines Committee. AGA clinical
practice guidelines on the management of mild-to-moderate
ulcerative colitis. Gastroenterology. 156:748–764. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Le Berre C, Roda G, Nedeljkovic Protic M,
Danese S and Peyrin-Biroulet L: Modern use of 5-aminosalicylic acid
compounds for ulcerative colitis. Expert Opin Biol Ther.
20:363–378. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ma C, Battat R, Dulai PS, Parker CE,
Sandborn WJ, Feagan BG and Jairath V: Innovations in oral therapies
for inflammatory bowel disease. Drugs. 79:1321–1335.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bonovas S, Nikolopoulos GK, Piovani D,
González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L and
Danese S: Comparative assessment of budesonide-MMX and mesalamine
in active, mild-to-moderate ulcerative colitis: A systematic review
and network meta-analysis. Br J Clin Pharmacol. 85:2244–2254.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Desreumaux P and Ghosh S: Review article:
Mode of action and delivery of 5-aminosalicylic acid-new evidence.
Aliment Pharmacol Ther. 24 (Suppl 1):S2–S9. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nakase H: Optimizing the use of current
treatments and emerging therapeutic approaches to achieve
therapeutic success in patients with inflammatory bowel disease.
Gut Liver. 14:7–19. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Stolfi C, De Simone V, Pallone F and
Monteleone G: Mechanisms of action of non-steroidal
anti-inflammatory drugs (NSAIDs) and mesalazine in the
chemoprevention of colorectal cancer. Int J Mol Sci.
14:17972–17985. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Eaden JA, Abrams KR and Mayberry JF: The
risk of colorectal cancer in ulcerative colitis: A meta-analysis.
Gut. 48:526–535. 2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Eaden J, Abrams K, Ekbom A, Jackson E and
Mayberry J: Colorectal cancer prevention in ulcerative colitis: A
case-control study. Aliment Pharmacol Ther. 14:145–153.
2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhao LN, Li JY, Yu T, Chen GC, Yuan YH and
Chen QK: 5-Aminosalicylates reduce the risk of colorectal neoplasia
in patients with ulcerative colitis: An updated meta-analysis. PLoS
One. 9(e94208)2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
van de Meeberg MM, Schultheiss JP,
Oldenburg B, Fidder HH and Huitema AD: Does the 5-aminosalicylate
concentration correlate with the efficacy of oral 5-aminosalicylate
and predict response in patients with inflammatory bowel disease? A
systematic review. Digestion. 101:245–261. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nardelli S, Pisani LF, Tontini GE, Vecchi
M and Pastorelli L: MMX® technology and its applications
in gastrointestinal diseases. Therap Adv Gastroenterol. 10:545–552.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ogata H, Aoyama N, Mizushima S, Hagino A
and Hibi T: Comparison of efficacy of multimatrix mesalazine 4.8
g/day once-daily with other high-dose mesalazine in active
ulcerative colitis: A randomized, double-blind study. Intest Res.
15:368–379. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wahlgren M, Axenstrand M, Håkansson Å,
Marefati A and Lomstein Pedersen B: In vitro methods to study colon
release: State of the Art and an outlook on new strategies for
better in-vitro biorelevant release media. Pharmaceutics.
11(95)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Abuhelwa AY, Foster DJR and Upton RN: A
quantitative review and meta-models of the variability and factors
affecting oral drug absorption-part I: Gastrointestinal pH. AAPS J.
18:1309–1321. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vertzoni M, Sulaiman S, Goumas K, Kersten
E, Anlahr J, Muenster U and Reppas C: Characteristics of contents
of lower intestine in the 65-74 years of age range could impact the
performance of safe and efficacious modified release products. J
Pharm Sci. 110:251–258. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Vinarov Z, Abdallah M, Agundez JAG,
Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M,
Griffin BT, Grimm M, et al: Impact of gastrointestinal tract
variability on oral drug absorption and pharmacokinetics: An UNGAP
review. Eur J Pharm Sci. 162(105812)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Vertzoni M, Augustijns P, Grimm M,
Koziolek M, Lemmens G, Parrott N, Pentafragka C, Reppas C, Rubbens
J, Van Den Αbeele J, et al: Impact of regional differences along
the gastrointestinal tract of healthy adults on oral drug
absorption: An UNGAP review. Eur J Pharm Sci. 134:153–175.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nugent SG, Kumar D, Rampton DS and Evans
DF: Intestinal luminal pH in inflammatory bowel disease: Possible
determinants and implications for therapy with aminosalicylates and
other drugs. Gut. 48:571–577. 2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vertzoni M, Goumas K, Söderlind E,
Abrahamsson B, Dressman JB, Poulou A and Reppas C: Characterization
of the ascending colon fluids in ulcerative colitis. Pharm Res.
27:1620–1626. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fallingborg J, Christensen LA, Jacobsen BA
and Rasmussen SN: Very low intraluminal colonic pH in patients with
active ulcerative colitis. Dig Dis Sci. 38:1989–1993.
1993.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Abuhelwa AY, Foster DJR and Upton RN: A
quantitative review and meta-models of the variability and factors
affecting oral drug absorption-part II: Gastrointestinal transit
time. AAPS J. 18:1322–1333. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Andreas CJ, Chen YC, Markopoulos C, Reppas
C and Dressman J: In vitro biorelevant models for evaluating
modified release mesalamine products to forecast the effect of
formulation and meal intake on drug release. Eur J Pharm Biopharm.
97:39–50. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Goyanes A, Hatton GB, Merchant HA and
Basit AW: Gastrointestinal release behaviour of modified-release
drug products: Dynamic dissolution testing of mesalazine
formulations. Int J Pharm. 484:103–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Karkossa F and Klein S: A biopredictive in
vitro comparison of oral locally acting mesalazine formulations by
a novel dissolution model for assessing intraluminal drug release
in individual subjects. J Pharm Sci. 107:1680–1689. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Leifeld L, Pfützer R, Morgenstern J,
Gibson PR, Marakhouski Y, Greinwald R, Mueller R and Kruis W:
Mesalazine granules are superior to Eudragit-L-coated mesalazine
tablets for induction of remission in distal ulcerative colitis-a
pooled analysis. Aliment Pharmacol Ther. 34:1115–1122.
2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Christensen LA, Slot O, Sanchez G, Boserup
J, Rasmussen SN, Bondesen S, Hansen SH and Hvidberg EF: Release of
5-aminosalicylic acid from Pentasa during normal and accelerated
intestinal transit time. Br J Clin Pharmacol. 23:365–369.
1987.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Koziolek M, Grimm M, Becker D, Iordanov V,
Zou H, Shimizu J, Wanke C, Garbacz G and Weitschies W:
Investigation of pH and temperature profiles in the GI tract of
fasted human subjects using the intellicap(®) system. J
Pharm Sci. 104:2855–2863. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ito H, Iida M, Matsumoto T, Suzuki Y,
Sasaki H, Yoshida T, Takano Y and Hibi T: Direct comparison of two
different mesalamine formulations for the induction of remission in
patients with ulcerative colitis: A double-blind, randomized study.
Inflamm Bowel Dis. 16:1567–1574. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Frieri G, Giacomelli R, Pimpo M, Palumbo
G, Passacantando A, Pantaleoni G and Caprilli R: Mucosal
5-aminosalicylic acid concentration inversely correlates with
severity of colonic inflammation in patients with ulcerative
colitis. Gut. 47:410–414. 2000.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hirayama M, Toda R, Ozaki T, Hasegawa J,
Nakamura T, Naraki Y, Haraguchi Y, Hori Y, Tanaka T, Takei M, et
al: Concentration dependence of 5-aminosalicylic acid
pharmacological actions in intestinal mucosa after oral
administration of a pH-dependent formulation. Mol Pharm.
8:1083–1089. 2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
D'Incà R, Paccagnella M, Cardin R, Pathak
S, Baldo V, Giron MC and Sturniolo GC: 5-ASA colonic mucosal
concentrations resulting from different pharmaceutical formulations
in ulcerative colitis. World J Gastroenterol. 19:5665–5670.
2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yamamoto Y, Masuda S, Nakase H, Matsuura
M, Maruyama S, Hisamatsu T, Suzuki Y and Matsubara K: Influence of
pharmaceutical formulation on the mucosal concentration of
5-aminosalicylic acid and N-acetylmesalamine in Japanese patients
with ulcerative colitis. Biol Pharm Bull. 42:81–86. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fukuda T, Naganuma M, Takabayashi K,
Hagihara Y, Tanemoto S, Nomura E, Yoshimatsu Y, Sugimoto S, Nanki
K, Mizuno S, et al: Mucosal concentrations of
N-acetyl-5-aminosalicylic acid related to endoscopic activity in
ulcerative colitis patients with mesalamine. J Gastroenterol
Hepatol. 35:1878–1885. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kawashima K, Ishihara S, Yuki T, Onishi K,
Kushiyama Y, Fujishiro H, Miyaoka Y, Yuki M, Komazawa Y, Tanimura
T, et al: Therapeutic efficacy of pH-dependent release formulation
of mesalazine on active ulcerative colitis resistant to
time-dependent release formulation: Analysis of fecal calprotectin
concentration. Biomed Res Int. 2014(342751)2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yasutomi E, Hiraoka S, Yamamoto S, Oka S,
Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K,
et al: Switching between three types of mesalazine formulation and
sulfasalazine in patients with active ulcerative colitis who have
already received high-dose treatment with these agents. J Clin Med.
8(2019)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nagahori M, Kochi S, Hanai H, Yamamoto T,
Nakamura S, Omuro S, Watanabe M and Hibi T: OPTIMUM Study Group.
Real life results in using 5-ASA for maintaining mild to moderate
UC patients in Japan, a multi-center study, OPTIMUM Study. BMC
Gastroenterol. 17(47)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ito H, Iida M, Matsumoto T, Suzuki Y, Aida
Y, Yoshida T, Takano Y and Hibi T: Direct comparison of two
different mesalamine formulations for the maintenance of remission
in patients with ulcerative colitis: A double-blind, randomized
study. Inflamm Bowel Dis. 16:1575–1582. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gibson PR, Fixa B, Pekárková B, Bátovský
M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH and Greinwald
R: Comparison of the efficacy and safety of Eudragit-L-coated
mesalazine tablets with ethylcellulose-coated mesalazine tablets in
patients with mild to moderately active ulcerative colitis. Aliment
Pharmacol Ther. 23:1017–1026. 2006.PubMed/NCBI View Article : Google Scholar
|
